Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_2593_Библиотеки_им_академика_М_И_Перельмана
.pdf
Given the complexities of data on drug interactions and the
complexities within the health care systems, health care providers
have become increasingly challenged on devising optimal
approaches to managing drug interactions.3 Patient safety initiatives
have expanded in efforts to improve the health care delivery system
with medication error prevention as a high-priority area. Medication
errors may be related to professional practice, health care products,
procedures, and systems, including prescribing, order
communication, product labeling, packaging, nomenclature,
compounding, dispensing, distribution, administration, education,
monitoring, and use.
2,4
Because exposure to DDIs is a significant
source of preventable drug-related harm, appropriate medication
use, including drug interaction management, will avoid medication
errors.
5
Although the majority of drug interactions are clinically
insignificant, in certain circumstances, drug interactions are
considered to be highly significant and can cause harm. Patients
should be informed of the importance of maintaining a complete
medication profile, including OTC medications, herbs, and dietary
supplements. The incorporation of pharmacogenetic information into
risk assessment of patients will improve our ability to prevent DDIs
and to better evaluate interactions with biologic drugs.
More well-controlled studies are needed after drug approvals.
Population-based studies are useful to determine the severity of,
incidence of, and clinical importance of drug interactions.
Pharmacogenetic research can further improve the precision of DDI
evidence and CDS by identifying patient-specific predisposing
factors. Future directives will identify the most appropriate process to
rate the quality of DDI evidence and provided graded
recommendations to reduce the risk of adverse consequences.
5
KEY REFERENCES AND WEBSITES
https://t.me/medicina_free
1.
2.
3.
A full list of references for this chapter can be found at
http://thepoint.lww.com/AT12e. The following are the key references
and websites for this chapter, with the corresponding reference
number in this chapter found in parentheses after the reference.
Key References
Caterina P, Di Paolo A, Giofrè C, et al. Pharmacokinetic drug-drug interaction and
their implication in clinical management. J Res Med Sci. 2013;18: 601–610. (3)
Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its
drug and food interactions. Arch Intern Med. 2005;165:1095–1106. (68)
Scheife RT, Hines LE, Boyce RD, et al. Consensus recommendations for
systematic evaluation of drug-drug interaction evidence for clinical decision
support. Drug Saf. 2015;38:197–206. (5)
Tilson H, Hines LE, McEvoy G, et al. Recommendations for selecting drug-drug
interactions for clinical decision support. Am J Health Syst Pharm.
2016;73(8):576–585. (123)
Key Websites
IBM Micromedex® Drug Interaction Checking (electronic version). IBM Watson
Health. Accessed July 4, 2021. https://www-micromedexsolutionscom.ezproxymcp.flo.org/ (73)
Interactions. Lexicomp. Wolters Kluwer Health, Inc. Accessed July 4, 2021.
http://online.lexi.com (61)
COMPLETE REFERENCES CHAPTER 3 DRUG
INTERACTIONS
Robertson S, Penzak S. Drug interactions. In: Atkinson AJ Jr, Abernethy DR,
Daniels CE, Dedrick RL, Markey SP, eds. Principles of Clinical
Pharmacology. 3rd ed. Elsevier Academic Press; 2012:239–257.
Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse
reactions caused by drug-drug interactions. Expert Opin Drug Saf.
2012;11(1):83–94.
Caterina P, Di Paolo A, Giofrè C, et al. Pharmacokinetic drug-drug interaction
and their implication in clinical management. J Res Med Sci. 2013;18:601–
610.
https://t.me/medicina_free
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
Derendorf H, et al. Variability. In: Derendorf H, Schmidt S, eds. Rowland and
Tozer’s Clinical Pharmacokinetics and Pharmacodynamics: Concepts and
Applications. 5th ed. Wolters Kluwer Lippincott Williams & Wilkins;
2020:361–392.
Scheife RT, Hines LE, Boyce RD, et al. Consensus recommendations for
systematic evaluation of drug-drug interaction evidence for clinical decision
support. Drug Saf. 2015;38:197–206.
Derendorf H, et al. Drug Interactions. In: Derendorf H, Schmidt S, eds.
Rowland and Tozer’s Clinical Pharmacokinetics and Pharmacodynamics:
Concepts and Applications. 5th ed. Wolters Kluwer Lippincott Williams &
Wilkins; 2020:531–576.
Oates JA. The science of drug therapy. In: Brunton LL, ed. Goodman &
Gilman’s The Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill,
Medical Publishing Division; 2006.
Hines LE, Murphy JE. Potentially harmful drug-drug interactions in the
elderly: a review. Am J Geriatr Pharmacother. 2011;9(6):364–377.
Food and Drug Administration, U.S. Department of Health and Human
Services, Center for Drug Evaluation and Research. Clinical drug interaction
studies—cytochrome P450 enzyme- and transporter-mediated drug
interactions guidance for industry. January 2020. Accessed July 1, 2021.
https://www.fda.gov/regulatory-information/search-fda-guidancedocuments/clinical-drug-interaction-studies-cytochrome-p450-enzyme-andtransporter-mediated-drug-interactions
Sharifi H, Hasanloei MAV, Mahmoudi J. Polypharmacy-induced drug-drug
interactions; threat to patient safety. Drug Res. 2014;64:633–637.
Wallace J, Paauw DS. Appropriate prescribing and important drug
interactions in older adults. Med Clin North Am. 2015;99:295–310.
Gnjidic D, Johnell K. Clinical implications from drug-drug and drug-disease
interactions in older people. Clin Exp Pharmacol Physiol. 2013;40:320–325.
Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab.
2011;12:601–610.
Maeda K. Systematic review of the effects of improvement of prescription to
reduce the number of medications in the elderly with polypharmacy.
Yakugaku Zasshi. 2009;129(5):631–645.
Pizzuti R, Caffari B, Binkin N; Gruppo ARGENTO. Prescription drugs and the
elderly: results of the Agrento study. Ig Sanita Pubbl. 2006;62(1):11–26.
Kalula SZ. Drugs and the older person. CME. 2007;25(9):422–425.
Shapiro LE, Shear NH. Drug interactions: proteins, pumps, and P-450s. J
Am Acad Dermatol. 2002;47:467–484.
Sitar DS. Aging issues in drug disposition and efficacy. Proc West Pharmacol
Soc. 2007;50:16–20.
Polidoro A, Dornbusch T, Vestri A, Di Bona S, Alessandri C. Frailty and
disability in the elderly: a diagnostic dilemma. Arch Gerontol Geriatr.
https://t.me/medicina_free
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
2011;52(2):e75–e78.
Hubbard RE, Woodhouse KW. Frailty, inflammation and the elderly.
Biogerontology. 2010;11(5):635–641.
Turnheim K. When drug therapy gets old: pharmacokinetics and
pharmacodynamics in the elderly. Exp Gerontol. 2003;38:843–853.
Costa AJ. Potential drug interactions in an ambulatory geriatric population.
Fam Pract. 1991;8:234–236.
Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O’Mara EM Jr,
Hall SD. The contribution of intestinal and hepatic CYHP3A4 to the
interaction between midazolam and clarithromycin. Clin Pharmacol Ther.
1998;64:133–143.
Bhardwaj S, Selvarajah S, Schneider EB. Muscular effects of statins in the
elderly female; a review. Clin Interv Aging. 2013;8:47–59.
Blouin RA, Ensom MHH. Special pharmacokinetic considerations in the
obese. In: Burton ME, Shaw LM, Schentag JJ, Evans WE, eds. Applied
Pharmacokinetics & Pharmacodynamics: Principles of Therapeutic Drug
Monitoring. 4th ed. Lippincott Williams & Wilkins; 2006:231–241.
McCabe BJ. Prevention of food-drug interactions with a special emphasis on
older adults. Curr Opin Clin Nutr Metab Care. 2004;7:21–26.
Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update.
Clin Pharmacokinet. 1999;36(6):425–438.
Samer CF, Ing Lorenzini K, Rollason V, Daali Y, Desmeules JA. Applications
of CYP450 testing in the clinical settings. Mol Diagn Ther. 2013;17:165–184.
Grattagliano I, Portincasa P, D’Ambrosio G, Palmieri VO, Palasciano G.
Avoiding drug interactions: here’s help. J Fam Pract. 2010;59(6):322–329.
Corsonello A, Abbatecola AM, Fusco S, et al. The impact of drug interactions
and polypharmacy on antimicrobial therapy in the elderly. Clin Microbiol
Infect. 2015;21(1):20–26.
Zhou J, Poloyac SM. The effect of therapeutic hypothermia on drug
metabolism and drug response: cellular mechanisms to organ function.
Expert Opin Drug Metab Toxicol. 2011;7(7):803–816.
Thelen K, Dressman JB. Cytochrome P450-mediated metabolism in the
human gut. J Pharm Pharmacol. 2009;61:541–558.
Finch A, Pillans P. P-glycoprotein and its role in drug-drug interactions. Aust
Prescr. 2014;37:137–139.
Doligalski CT, Tong Logan A, Silverman A. Drug interactions: a primer for the
gastroenterologist. Gastroenterol Hepatol. 2012;8(6):376–383.
Andrus MR. Oral anticoagulant drug interactions with statins: case report of
fluvastatin and review of the literature. Pharmacotherapy. 2004;24:285–290.
Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for
management of clinically significant drug-drug interactions with statins and
select agents used in patients with cardiovascular disease: a scientific
https://t.me/medicina_free
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
statement from the American Heart Association. Circulation. 2016;134:e468–
e495.
Horn JR, Hansten PD. Statins and OATP interactions. Pharm Times.
2014:42. http://www.hanstenandhorn.com/hh-article-June-2014.pdf
Manzi SF, Shannon M. Drug interactions—a review. Clin Ped Emerg Med.
2005;6:93–102.
Middleton RK. Drug interactions. In: Quan H, Helms RA, Quan DJ,
Hernfindal ET, Gourley DR, eds. Textbook of Therapeutics Drug and Disease
Management. 8th ed. Lippincott Williams and Wilkins; 2006.
Benet LZ, Hoener B. Changes in plasma protein binding have little clinical
relevance. Clin Pharmcol Ther. 2002;71:115–121.
Boobis A, Watelet JB, Whomsley R, Benedetti MS, Demoly P, Tipton K. Drug
interactions. Drug Metab Rev. 2009;41(3):486–527.
Zhou SF, Xue CC, Yu X-Q, Li C, Wang G. Clinically important drug
interactions potentially involving mechanism-based inhibition of cytochrome
P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit.
2007;29(6):687–710.
Lynch T, Price A. The effect of cytochrome P450 metabolism on drug
response, interactions, and adverse effects. Am Fam Physician.
2007;76(3):391–396.
Ladda MA, Goralski KB. The effects of CKD on cytochrome P450-mediated
drug metabolism. Adv Chronic Kidney Dis. 2016;23(2):67–75.
Anaisi N. Drug interactions involving immunosuppressive agents. Graft.
2001;4(4):232–247.
Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug
interactions. Br J Clin Pharmacol. 1998;46(2):101–110.
Evans AM. Influence of dietary components on the gastrointestinal
metabolism and transport of drugs. Ther Drug Monit. 2000;22(1):131–136.
Thummel KE, Kunze KL, Shen DD, et al. Metabolically-based drug-drug
interactions. Principles and mechanisms. In: Levy RH, Thummel KE, Trayer
WF, Hansten PD, Eichelbaum M, eds. Metabolic Drug Interactions. Lippincott
Williams & Wilkins; 2000:3–47.
Bachmann KA, Ring BJ, Wrighton SA. Drug-drug interactions and the
cytochromes P450. In: Lee JS, Obach RS, Fisher MB, eds. Drug
Metabolizing Enzymes: Cytochrome P450 and Other Enzymes in Drug
Discovery and Development. Marcel Dekker, Inc; 2003:311–336.
Obach RS. Drug-drug interactions: an important negative attribute in drugs.
Drugs Today. 2003;39:301–338.
Weaver RJ. Assessment of drug-drug interactions: concepts and
approaches. Xeobiotica. 2001;31:499–538.
Cheng JW, Frishman WH, Aronow WS. Updates of cytochrome P450mediated cardiovascular drug interactions. Am J Ther. 2009;16:155–163.
https://t.me/medicina_free
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
Sabol BJ, Basa RR, Wilkins CE. Malabsorption-associated warfarin
resistance. Am J Health Syst Pharm. 2009;66:1548–1553.
Gugler R, Manion CV, Azarnoff DL. Phenytoin: pharmacokinetics and
bioavailability. Clin Pharm Ther. 1976;19:135–142.
Maynard GA, Jones KM, Guidry JR. Phenytoin absorption from tube
feedings. Arch Intern Med. 1987;147:1821.
Jung D, Powell JR, Walson P, Perrier D. Effect of dose on phenytoin
absorption. Clin Pharmacol Ther. 1980;28:479–485.
Martin E, Tozer TN, Sheiner LB, Riegelman S. The clinical pharmacokinetics
of phenytoin. J Pharmacokinet Biopharm. 1977;5:579–596.
Gubbins PO, Bertch KE. Drug absorption in gastrointestinal disease and
surgery. Clinical pharmacokinetic and therapeutic implications. Clin
Pharmacokinet. 1991;21:431–447.
Gulseth MP, Grice GR, Dager WE. Pharmacogenomics of warfarin:
uncovering a piece of the warfarin mystery. Am J Health Syst Pharm.
2009;66:123–133.
Gorbach SL. Microbiology of the gastrointestinal tract. In: Baron S, ed.
Medical Microbiology. 4th ed. University of Texas Medical Branch at
Galveston; 1996. Accessed July 12, 2021.
http://www.ncbi.nlm.nih.gov/books/NBK7670/
Interactions. Lexicomp. Wolters Kluwer Health, Inc. Accessed July 4, 2021.
http://online.lexi.com
Preston CL, ed. Stockley’s Drug Interactions. 12th ed. Pharmaceutical Press;
2019.
Foinard A, Décaudin B, Barthélémy C, Debaene B, Odou P. Impact of
physical incompatibility on drug mass flow rates: example of furosemidemidazolam incompatibility. Ann Intensive Care. 2012;2:28.
Bungard TJ, Yakiwchuk E, Foisy M, Brocklebank C. Drug interactions
involving warfarin: practice tool and practical management tips. CPJ/RPC.
2011;144(1):21–25.e9.
Horn JR, Hansten PD. Time course for enzyme induction and deinduction.
Pharm Times. 2011;77(4):46
Pleuvry BJ. Pharmacodynamic and pharmacokinetic drug interactions.
Anaesth Intensive Care Med. 2005;6(4):129–133.
Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen
and other risk factors for excessive warfarin anticoagulation. JAMA.
1998;276:657–662.
Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin
and its drug and food interactions. Arch Intern Med. 2005;165:1095–1106.
Lopes RD, Horowitz JD, Garcia DA, Crowther MA, Hylek EM. Warfarin and
acetaminophen interaction: a summary of the evidence and biologic
plausibility. Blood. 2011;118:6269–6273.
https://t.me/medicina_free
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
Leong D, Wu PE. Warfarin and acetaminophen interaction in a 47-year-old
woman. CMAJ. 2020;192(19):E506–E508. doi:10.1503/cmaj.191532
Yue Q, Bergquist C, Gerdén B. Safety of St John’s wort (Hypericum
perforatum). Lancet. 2000;355:576–577.
Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John’s wort
(Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin
Pharmacol. 2002;54:349–356.
IBM Micromedex® Drug Interaction Checking (electronic version). IBM
Watson Health. Accessed July 4, 2021. https://www-micromedexsolutionscom.ezproxymcp.flo.org/
Hatanaka T. Clinical pharmacokinetics of pravastatin: mechanisms of
pharmacokinetic events. Clin Pharmacokinet. 2000;39(6):397–412.
Munar MY, Singh H. Drug dosing adjustments in patients with chronic kidney
disease. Am Fam Physician. 2007;75:1487–1496.
PL detail-document. Clinically significant statin drug interactions.
Pharmacist’s Letter/Prescriber’s Letter. April 2012.
https://pharmacist.therapeuticresearch.com/Content/Segments/PRL/2016/Ma
r/Clinically-Significant-Statin-Drug-Interactions-9486
Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clin
Pharmacokinet. 2001;40(4):263–281.
McGrath CD, Hunter JM. Monitoring of neuromuscular block. Contin Educ
Anaesth Crit Care Pain. 2006;6(1):7–12.
Warr J, Thiboutot Z, Rose L, Mehta S, Burry LD. Current therapeutic uses,
pharmacology, and clinical considerations of neuromuscular blocking agents
for critically ill adults. Ann Pharmacother. 2011;45:1116–1126.
Roberts DJ, Hall RI. Drug absorption, distribution, metabolism and excretion
considerations in critically ill adults. Expert Opin Drug Metab Toxicol.
2013;9(9):1067–1084.
Smith BS, Yogaratnam D, Levasseur-Franklin KE, Forni A, Fong J.
Introduction to drug pharmacokinetics in the critically ill patient. Chest.
2012;141(5):1327–1336.
Cawley MJ. Mechanical ventilation: a tutorial for pharmacists.
Pharmacotherapy. 2007;27(2):250–266.
Hraiech S, Forel J-M, Papazian L. The role of neuromuscular blockers in
ARDS: benefits and risks. Curr Opin Crit Care. 2012;18:495–502.
DeJonghe B. Paresis acquired in the intensive care unit: a prospective
multicenter study. JAMA. 2002;288:2859–2867.
Murray MJ, DeBlock H, Erstad B, et al. Clinical practice guidelines for
sustained neuromuscular blockade in the adult critically ill patient. Crit Care
Med. 2016;44(11):2079–2103.
American College of Critical Care Medicine of the Society of Critical Care
Medicine, American Society of Health-System Pharmacists, American
College of Chest Physicians. Clinical practice guidelines for sustained
https://t.me/medicina_free
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
neuromuscular blockade in the adult critically ill patient. Am J Health Sys
Pharm. 2002;59:179–195.
Papazian L, Forel J-M, Gacouin A, et al; ACURASYS Study Investigators.
Neuromuscular blockers in early acute respiratory distress syndrome. N Engl
J Med. 2010;363(12):1107–1116.
Sunjic KM, Webb AC, Šunjic´ I, Creus MP, Folse SL. Pharmacokinetic and
other considerations for drug therapy during targeted temperature
management. Crit Care Med. 2015;43:2228–2238.
Kisor DF, Schmith VD. Clinical pharmacokinetics of cisatracurium besilate.
Clin Pharmacokinet. 1999;36(1):27–40.
Lagneau F, D'honneur G, Plaud B, et al. A comparison of two depths of
prolonged neuromuscular blockade induced by cisatracurium in mechanically
ventilated critically ill patients. Intensive Care Med. 2002;28:1735–1741.
Sessler CN. Train-of-four to monitor neuromuscular blockade? Chest.
2004;126(4):1018–1022.
Latcha S. Electrolyte disorders in critically ill patients. In: Oropello JM,
Pastores SM, Kvetan V, eds. Critical Care. McGraw Hill. Accessed July 12,
2021. https://accessmedicine-mhmedicalcom.ezproxymcp.flo.org/content.aspx?bookid=1944§ionid=143517373
Hibbs RE, Zambon AC. Nicotine and agents acting at the neuromuscular
junction and autonomic ganglia. In: Brunton LL, Hilal-Dandan R, Knollmann
BC, eds. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics.
13th ed. McGraw Hill. Accessed July 12, 2021. https://accesspharmacymhmedical-com.ezproxymcp.flo.org/content.aspx?
bookid=2189§ionid=167889972
Kindler CH, Verotta D, Gray AT, Gropper MA, Yost CS. Additive inhibition of
nicotinic acetylcholine receptors by corticosteroids and the neuromuscular
blocking drug vecuronium. Anesthesiology. 2000;92:821–832.
Price D, Kenyon NJ, Stollenwerk N. A fresh look at paralytics in the critically
ill: real promise and real concern. Ann Intensive Care. 2012;2:43.
Waitz A, Drube CG, Moss EL Jr, Oden EM, Bailey JV. Biological aspects of
the interaction between gentamicin and carbenicillin. J Antibiot.
1974;25:219–225.
Shwed JA. Lack of effect of clavulanic acid on aminoglycoside inactivation by
ticarcillin. J Infect Dis Pharmacother. 1995;1(2):35–43.
Walterspiel JN, Feldman S, Van R, Ravis WR. Comparative inactivation of
isepamicin, amikacin, and gentamicin by nine β-lactam and two β-lactamase
inhibitors, cilastatin and heparin. Antimicrob Agents Chemother.
1991;35(9):1875–1878.
Pickering LK, Rutherford I. Effect of concentration and time upon inactivation
of tobramycin, gentamicin, netilmicin and amikacin by azlocillin, carbenicillin,
mecillinam, mezlocillin and piperacillin. J Pharmacol Exp Ther.
1981;217:345–349.
https://t.me/medicina_free
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
American Society of Health-System Pharmacists. AHFS Drug Information®—
2021st ed. American Society of Health-System Pharmacists®. 2021.
STAT!Ref Online Electronic Medical Library. Accessed July 11, 2021.
https://online.statref.com/document/zrgja2xRlTkSeOsK3G0o7N
Taber HW, Mueller JP, Miller PF, Arrow AS. Bacterial uptake of
aminoglycoside antibiotics. Microbiol Rev. 1987;51(4):439–457.
Leggett JE. Aminoglycosides. In: Bennett JE, Dolin R, Blaser MJ, eds.
Mandell, Douglas, and Bennett’s Principles and Practice of Infectious
Diseases. 9th ed. Elsevier Health Sciences; 2020. Accessed July 12, 2021.
https://www-r2librarycom.ezproxymcp.flo.org/Resource/Title/0323482554/ch0025s0003
Davis BD. Bactericidal synergism between β-lactams and aminoglycosides:
mechanism and possible therapeutic implications. Rev Infect Dis.
1982;4(2):237–245.
Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd
LA. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib,
and nilotinib. Blood. 2011;117(8):e75–e87.
Rochat B, Fayet A, Widmer N, et al. Imatinib metabolite profiling in parallel to
imatinib quantification in plasma of treated patients using liquid
chromatography-mass spectrometry. J Mass Spectrom. 2008;43(6):736–752.
Peng B, Lloyd P, Schran H, et al. Clinical pharmacokinetics of imatinib. Clin
Pharmacokinet. 2005;44(9):879–894.
Kompendium ch [homepage]. Compendium Suisse des medicaments 2010
[updated 2010]. Accessed March 10, 2017. http://www.kompendium.ch/
Brendel C, Scharenberg C, Dohse M. Imatinib mesylate and nilotinib (AMN
107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic
stem cells. Leukemia. 2007;21(6):1267–1275.
Ozvegy-Laczka C, Hegedus T, Várady G, et al. High-affinity interaction of
tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol
Pharmacol. 2004;65(6):1485–1495.
White DL, Saunders VA, Dang P, et al. OCT-1-mediated influx is a key
determinant of the intracellular uptake of imatinib but not nilotinib (AMN 107):
reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib.
Blood. 2006;108(2):687–704.
Van Erp NP, Gelderblom H, Guchelaar H-J. Clinical pharmacokinetics of
tyrosine kinase inhibitors. Cancer Treat Rev. 2009;35(8):692–706.
Petain A, Kattygnarath D, Azard J, et al. Population pharmacokinetics and
pharmacogenetics of imatinib in children and adults. Clin Cancer Res.
2008;14(21):7102–7109.
Widmer N, Decosterd LA, Csajka C, et al. Population pharmacokinetics
ofimatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol.
2006;62(1):97–112.
https://t.me/medicina_free
114.
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
Widmer N, Decosterd LA, Leyvraz S, et al. Relationship of imatinib-free
plasma levels and target genotype with efficacy and tolerability. Br J Cancer.
2008;98(10):1633–1640.
Azuma M, Nishioka Y, Aono Y, et al. Role of alpha 1-acid glycoprotein in
therapeutic antifibrotic effects of imatinib with macrolides in mice. Am J
Respir Crit Care Med. 2007;176(12):1243–1250.
Dutreix C, Peng B, Mehring G, et al. Pharmacokinetic interaction between
ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer
Chemother Pharmacol. 2004;54(4):290–294.
Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ. Effect of St
John’s wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther.
2004;76(4):323–329.
Smith P, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ. The
influence of St. John’s wort on the pharmacokinetics and protein binding of
imatinib mesylate. Pharmacotherapy. 2004;24(11):1508–1514.
Recoche I, Rousseau V, Bourrel R, et al. Drug-drug interactions with imatinib:
an observational study. Medicine. 2016;95(40):e5076.
Cholongitas E, Pipili C, Katsogridakis K, Relos K, Dasenaki M. Dermatitis
after suspected imatinib-levothyroxine interaction in a patient with
gastrointestinal stromal tumor. Cancer Chemother Pharmacol.
2008;61:1083–1084.
De Grrot JWB, Zonnenberg BA, Plukker JTM, van Der Graaf WTA, Links TP.
Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin
Pharmacol Ther. 2005;78:433–438.
Horn JR, Hansten PD, Chan L-N. Proposal for a new tool to evaluate drug
interaction cases. Ann Pharmacother. 2007;41(4):674–680.
Tilson H, Hines LE, McEvoy G, et al. Recommendations for selecting drugdrug interactions for clinical decision support. Am J Health Syst Pharm.
2016;73(8):576–585.
Hansten PD. Drug interaction management. Pharm World Sci.
2003;25(3):94–97.
https://t.me/medicina_free
Соседние файлы в папке Библиотека им академика М.И. Перельмана